The compound BTB06584 is an IF1-dependent selective inhibitor of the mitochondrial F1Fo-ATPase

British Journal of Pharmacology

Volumn 171, Issue 18, 2014, Pages 4193-4206

  Ivanes, Fabrice ^a,d,e   Faccenda, Danilo ^b   Gatliff, Jemma ^b   Ahmed, Ahmed A ^a,b   Cocco, Stefania ^c   Cheng, Carol Ho Ka ^b   Allan, Emma ^a,b   Russell, Claire ^b   Duchen, Michael R ^a   Campanella, Michelangelo ^a,b,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL VETERINARY COLLEGE   (United Kingdom)

^c EUROPEAN BRAIN RESEARCH INSTITUTE   (Italy)

^d CarMeN   (France)

^e UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2-NITRO-5-(PHENYLSULFONYL)PHENYL 4-CHLOROBENZOATE; ADENOSINE TRIPHOSPHATE; ATPASE INHIBITORY PROTEIN; CHLOROBENZOIC ACID DERIVATIVE; ENZYME INHIBITOR; HEMOGLOBIN; PROTEIN; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATASE; SULFONE;

ANIMAL; ANIMAL EMBRYO; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL DEATH; CELL LINE; DRUG EFFECTS; HELA CELL LINE; HEMOLYSIS; HUMAN; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MOUSE; NERVE CELL; OXYGEN CONSUMPTION; REPERFUSION INJURY; ZEBRA FISH;

ADENOSINE TRIPHOSPHATE; ANIMALS; CELL DEATH; CELL LINE; CHLOROBENZOATES; EMBRYO, NONMAMMALIAN; ENZYME INHIBITORS; HELA CELLS; HEMOGLOBINS; HEMOLYSIS; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, INBRED C57BL; MITOCHONDRIA; NEURONS; OXYGEN CONSUMPTION; PROTEINS; PROTON-TRANSLOCATING ATPASES; REPERFUSION INJURY; SULFONES; ZEBRAFISH;

EID: 84897432317     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12638     Document Type: Article

References (53)

1. Atwal KS, Wang P, Rogers WL, Sleph P, Monshizadegan H, Ferrara FN, et al. (2004). Small molecule mitochondrial F1F0 ATPase hydrolase inhibitors as cardioprotective agents. Identification of 4-(N-arylimidazole)-substituted benzopyran derivatives as selective hydrolase inhibitors. J Med Chem 47: 1081-1084.
2. Cabezon E, Butler PJ, Runswick MJ, Walker JE, (2000). Modulation of the oligomerization state of the bovine F1-ATPase inhibitor protein, IF1, by pH. J Biol Chem 275: 25460-25464.
3. Cabezon E, Runswick MJ, Leslie AG, Walker JE, (2001). The structure of bovine IF(1), the regulatory subunit of mitochondrial F-ATPase. EMBO J 20: 6990-6996.
4. Campanella M, Casswell E, Chong S, Farah Z, Wieckowski MR, Abramov AY, et al. (2008). Regulation of mitochondrial structure and function by the F1Fo-ATPase inhibitor protein, IF1. Cell Metab 8: 13-25.
5. Capuano F, Guerrieri F, Papa S, (1997). Oxidative phosphorylation enzymes in normal and neoplastic cell growth. J Bioenerg Biomembr 29: 379-384.
6. Carunchio I, Pieri M, Ciotti MT, Albo F, Zona C, (2007). Modulation of AMPA receptors in cultured cortical neurons induced by the antiepileptic drug levetiracetam. Epilepsia 48: 654-662.
7. Chatham J, Gilbert HF, Radda GK, (1988). Inhibition of glucose phosphorylation by fatty acids in the perfused rat heart. FEBS Lett 238: 445-449.
8. Chinopoulos C, (2011). Mitochondrial consumption of cytosolic ATP: not so fast. FEBS Lett 585: 1255-1259.
9. Chinopoulos C, Gerencser AA, Mandi M, Mathe K, Torocsik B, Doczi J, et al. (2010). Forward operation of adenine nucleotide translocase during F0F1-ATPase reversal: critical role of matrix substrate-level phosphorylation. FASEB J 24: 2405-2416.
10. Claycomb WC, Lanson NA Jr, Stallworth BS, Egeland DB, Delcarpio JB, Bahinski A, et al. (1998). HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc Natl Acad Sci U S A 95: 2979-2984.
11. Duchen MR, (2000). Mitochondria and Ca2+ in cell physiology and pathophysiology. Cell Calcium 28: 339-348.
12. Duchen MR, Surin A, Jacobson J, (2003). Imaging mitochondrial function in intact cells. Methods Enzymol 361: 353-389.
13. Dudas K, Lappas G, Stewart S, Rosengren A, (2011). Trends in out-of-hospital deaths due to coronary heart disease in Sweden (1991 to 2006). Circulation 123: 46-52.
14. Dugan LL, Bruno VM, Amagasu SM, Giffard RG, (1995). Glia modulate the response of murine cortical neurons to excitotoxicity: glia exacerbate AMPA neurotoxicity. J Neurosci 15: 4545-4555.
15. Faccenda D, Campanella M, (2012). Molecular regulation of the mitochondrial F(1)F(o)-ATPsynthase: physiological and pathological significance of the inhibitory factor 1 (IF(1)). Int J Cell Biol 2012: 367934.
16. Faccenda D, Tan CH, Seraphim A, Duchen MR, Campanella M, (2013). IF1 limits the apoptotic-signalling cascade by preventing mitochondrial remodelling. Cell Death Differ 20: 686-697.
17. Giorgio V, von Stockum S, Antoniel M, Fabbro A, Fogolari F, Forte M, et al. (2013). Dimers of mitochondrial ATP synthase form the permeability transition pore. Proc Natl Acad Sci U S A 110: 5887-5892.
18. Goldberg MP, Choi DW, (1993). Combined oxygen and glucose deprivation in cortical cell culture: calcium-dependent and calcium-independent mechanisms of neuronal injury. J Neurosci 13: 3510-3524.
19. Green DW, Grover GJ, (2000). The IF(1) inhibitor protein of the mitochondrial F(1)F(0)-ATPase. Biochim Biophys Acta 1458: 343-355.
20. Grover GJ, Atwal KS, Sleph PG, Wang FL, Monshizadegan H, Monticello T, et al. (2004). Excessive ATP hydrolysis in ischemic myocardium by mitochondrial F1F0-ATPase: effect of selective pharmacological inhibition of mitochondrial ATPase hydrolase activity. Am J Physiol Heart Circ Physiol 287: H1747-H1755.
21. Hall AM, Unwin RJ, Parker N, Duchen MR, (2009). Multiphoton imaging reveals differences in mitochondrial function between nephron segments. J Am Soc Nephrol 20: 1293-1302.
22. Harris DA, Das AM, (1991). Control of mitochondrial ATP synthesis in the heart. Biochem J 280 (Pt 3): 561-573.
23. Irwin JJ, Shoichet BK, (2005). ZINC-a free database of commercially available compounds for virtual screening. J Chem Inf Model 45: 177-182.
24. Jennings RB, Reimer KA, Steenbergen C, (1991). Effect of inhibition of the mitochondrial ATPase on net myocardial ATP in total ischemia. J Mol Cell Cardiol 23: 1383-1395.
25. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: Reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
26. Leyssens A, Nowicky AV, Patterson L, Crompton M, Duchen MR, (1996). The relationship between mitochondrial state, ATP hydrolysis, [Mg2+]i and [Ca2+]i studied in isolated rat cardiomyocytes. J Physiol 496 (Pt 1): 111-128.
27. Luciakova K, Kuzela S, (1984). Increased content of natural ATPase inhibitor in tumor mitochondria. FEBS Lett 177: 85-88.
28. Luft R, Ikkos D, Palmieri G, Ernster L, Afzelius B, (1962). A case of severe hypermetabolism of nonthyroid origin with a defect in the maintenance of mitochondrial respiratory control: a correlated clinical, biochemical, and morphological study. J Clin Invest 41: 1776-1804.
29. Manev H, Favaron M, Vicini S, Guidotti A, Costa E, (1990). Glutamate-induced neuronal death in primary cultures of cerebellar granule cells: protection by synthetic derivatives of endogenous sphingolipids. J Pharmacol Exp Ther 252: 419-427.
30. Matsuno-Yagi A, Hatefi Y, (1993). Studies on the mechanism of oxidative phosphorylation. Different effects of F0 inhibitors on unisite and multisite ATP hydrolysis by bovine submitochondrial particles. J Biol Chem 268: 1539-1545.
31. McGovern PG, Pankow JS, Shahar E, Doliszny KM, Folsom AR, Blackburn H, et al. (1996). Recent trends in acute coronary heart disease-mortality, morbidity, medical care, and risk factors. The Minnesota Heart Survey Investigators. N Engl J Med 334: 884-890.
32. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
33. Murata M, Akao M, O'Rourke B, Marban E, (2001). Mitochondrial ATP-sensitive potassium channels attenuate matrix Ca(2+) overload during simulated ischemia and reperfusion: possible mechanism of cardioprotection. Circ Res 89: 891-898.
34. Naylor E, Arredouani A, Vasudevan SR, Lewis AM, Parkesh R, Mizote A, et al. (2009). Identification of a chemical probe for NAADP by virtual screening. Nat Chem Biol 5: 220-226.
35. Paffett-Lugassy NN, Zon LI, (2005). Analysis of hematopoietic development in the zebrafish. Methods Mol Med 105: 171-198.
36. Papadimitriou C, Yapijakis C, Davaki P, (2004). Use of truncated pyramid representation methodology in three-dimensional reconstruction: an example. J Microsc 214 (Pt 1): 70-75.
37. Power J, Cross RL, Harris DA, (1983). Interaction of F1-ATPase, from ox heart mitochondria with its naturally occurring inhibitor protein. Studies using radio-iodinated inhibitor protein. Biochim Biophys Acta 724: 128-141.
38. Pullman ME, Monroy GC, (1963). A naturally occurring inhibitor of mitochondrial adenosine triphosphatase. J Biol Chem 238: 3762-3769.
39. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. (2012). Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 125: e2-e220.
40. Rosen D, Lewis AM, Mizote A, Thomas JM, Aley PK, Vasudevan SR, et al. (2009). Analogues of the nicotinic acid adenine dinucleotide phosphate (NAADP) antagonist Ned-19 indicate two binding sites on the NAADP receptor. J Biol Chem 284: 34930-34934.
41. Rouslin W, (1991). Regulation of the mitochondrial ATPase in situ in cardiac muscle: role of the inhibitor subunit. J Bioenerg Biomembr 23: 873-888.
42. Rouslin W, Erickson JL, Solaro RJ, (1986). Effects of oligomycin and acidosis on rates of ATP depletion in ischemic heart muscle. Am J Physiol 250 (3 Pt 2): H503-H508.
43. Rouslin W, Broge CW, Grupp IL, (1990). ATP depletion and mitochondrial functional loss during ischemia in slow and fast heart-rate hearts. Am J Physiol 259 (6 Pt 2): H1759-H1766.
44. Rouslin W, Frank GD, Broge CW, (1995). Content and binding characteristics of the mitochondrial ATPase inhibitor, IF1, in the tissues of several slow and fast heart-rate homeothermic species and in two poikilotherms. J Bioenerg Biomembr 27: 117-125.
45. Savoia C, Sisalli MJ, Di Renzo G, Annunziato L, Scorziello A, (2011). Rosuvastatin-induced neuroprotection in cortical neurons exposed to OGD/reoxygenation is due to nitric oxide inhibition and ERK1/2 pathway activation. Int J Physiol Pathophysiol Pharmacol 3: 57-64.
46. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. (2012). Fiji: an open-source platform for biological-image analysis. Nat Methods 9: 676-682.
47. Shah DI, Takahashi-Makise N, Cooney JD, Li L, Schultz IJ, Pierce EL, et al. (2012). Mitochondrial Atpif1 regulates haem synthesis in developing erythroblasts. Nature 491 (7425): 608-612.
48. Sharov VG, Todor A, Khanal S, Imai M, Sabbah HN, (2007). Cyclosporine A attenuates mitochondrial permeability transition and improves mitochondrial respiratory function in cardiomyocytes isolated from dogs with heart failure. J Mol Cell Cardiol 42: 150-158.
49. Vinogradov AD, (2000). Steady-state and pre-steady-state kinetics of the mitochondrial F(1)F(o) ATPase: is ATP synthase a reversible molecular machine? J Exp Biol 203 (Pt 1): 41-49.
50. Wang Y, Hirai K, Ashraf M, (1999). Activation of mitochondrial ATP-sensitive K(+) channel for cardiac protection against ischemic injury is dependent on protein kinase C activity. Circ Res 85: 731-741.
51. Westerfield M, (2007). The Zebrafish Book. A Guide for the Laboratory Use of Zebrafish (Danio rerio), 5th edn. Univ. of Oregon Press: Eugene.
52. Yamada EW, Huzel NJ, (1992). Distribution of the ATPase inhibitor proteins of mitochondria in mammalian tissues including fibroblasts from a patient with Luft's disease. Biochim Biophys Acta 1139: 143-147.
53. Yang WC, (1957). Effect of iodoacetate and iodoacetamide on oxygen uptake of heart mitochondria. Science 125 (3257): 1087.